Terms: = Gastric cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
2602 results:
1. The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with her2-negative gastric adenocarcinoma: a meta-analysis.
Li JB; Lai MY; Lin ZC; Guan WL; Sun YT; Yang J; Wang WX; Yang ZR; Qiu MZ
Cancer Immunol Immunother; 2024 May; 73(7):132. PubMed ID: 38753055
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced gastric cancer.
Yamaguchi K; Ito M; Isobe T; Koreishi S; Taguchi R; Uehara K; Ueno S; Imajima T; Kitazono T; Tsuchihashi K; Ohmura H; Yoshihiro T; Tanoue K; Nishiyori S; Iwama E; Maeda T; Akashi K; Baba E
JCO Precis Oncol; 2024 May; 8():e2300681. PubMed ID: 38748981
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract] [Full Text] [Related]
4. Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.
Yan J; Bhadane R; Ran M; Ma X; Li Y; Zheng D; Salo-Ahen OMH; Zhang H
Nat Commun; 2024 May; 15(1):3684. PubMed ID: 38693181
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
7. [A Case of Distal Gastrectomy and Left Segmentectomy for Hepatic Invasion of gastric cancer].
Nakayama Y; Koyama K; Shimizu K; Kanemoto R; Urata N; Komori K; Uchiyama M; Suzuki Y; Rino Y; Saito A
Gan To Kagaku Ryoho; 2024 Apr; 51(4):457-459. PubMed ID: 38644321
[TBL] [Abstract] [Full Text] [Related]
8. [A Case of Stage Ⅳ gastric cancer with Multiple Liver Metastases, Resected Primary Tumor after Chemotherapy, and Alive for 3.5 Years without Recurrence].
Nakagawa T; Yamamoto Y; Yanagawa S; Shiozaki S; Kaneko Y; Watanabe A; Nishina M; Takei D; Sumi Y; Yamaki M; Kurayoshi M; Hashizume J; Oshita A; Nakahara M; Noriyuki T
Gan To Kagaku Ryoho; 2024 Apr; 51(4):433-435. PubMed ID: 38644313
[TBL] [Abstract] [Full Text] [Related]
9. [A Case of Advanced gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
10. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
11. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract] [Full Text] [Related]
12. The prevalence and clinical significance of her2 expression in prostate adenocarcinoma.
Estephan F; Lap CJ; Banagan J; Antonio M; Liu S; Diao G; Rozalen AZ; Rajendran R; Krasnow S; Subrahmanyam R; Nava VE; Jain M
Ann Diagn Pathol; 2023 Dec; 67():152219. PubMed ID: 38622987
[TBL] [Abstract] [Full Text] [Related]
13. TOB1 modulates neutrophil phenotypes to influence gastric cancer progression and immunotherapy efficacy.
Zhang J; Li Y; Chen J; Huang T; Lin J; Pi Y; Hao H; Wang D; Liang X; Fu S; Yu J
Front Immunol; 2024; 15():1369087. PubMed ID: 38617839
[TBL] [Abstract] [Full Text] [Related]
14. Advances in the Imaging of Esophageal and Gastroesophageal Junction Malignancies.
Ruby L; Jayaprakasam VS; Fernandes MC; Paroder V
Hematol Oncol Clin North Am; 2024 Jun; 38(3):711-730. PubMed ID: 38575457
[TBL] [Abstract] [Full Text] [Related]
15. Establishment of a Novel cancer-Specific Anti-her2 Monoclonal Antibody H
Kaneko MK; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
[TBL] [Abstract] [Full Text] [Related]
16. [Surgical management of gastric cancer in the era of immunotherapy].
Li ZY; Jia YN; Lu XX; Guan GM; Wang Q
Zhonghua Wai Ke Za Zhi; 2024 May; 62(5):353-358. PubMed ID: 38548601
[TBL] [Abstract] [Full Text] [Related]
17. Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal cancers.
Lee J; Ku G
Hematol Oncol Clin North Am; 2024 Jun; 38(3):585-598. PubMed ID: 38521686
[TBL] [Abstract] [Full Text] [Related]
18. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
19. Novel metabolic biomarker for early detection and diagnosis to the patients with gastric cardia adenocarcinoma.
Wei MX; Yang Z; Wang PP; Zhao XK; Song X; Xu RH; Hu JF; Zhong K; Lei LL; Han WL; Yang MM; Zhou FY; Han XN; Fan ZM; Li J; Wang R; Li B; Wang LD
Cancer Med; 2024 Mar; 13(5):e7015. PubMed ID: 38491808
[TBL] [Abstract] [Full Text] [Related]
20. Locally misfolded her2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.
Arimori T; Mihara E; Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Takagi J; Kato Y
Structure; 2024 May; 32(5):536-549.e5. PubMed ID: 38460519
[TBL] [Abstract] [Full Text] [Related]
[Next]
